Evidence map›Paper›PMID 39623958›Full record

ArticleClinical and molecular hepatology2025

Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.

Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe.International journal of environmental research and public health · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meiyu WuDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jing MaDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xuehong WangDepartment of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Sini LiThe Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Chongqing TanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ouyang XieDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Andong LiDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Aaron G LimPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Xiaomin WanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

Central Universities of Central South University 2023ZZTS0924Health Commission of Hunan Province 202113050283High Performance Computing Center of Central South UniversityHunan Provincial Natural Science Foundation of China 2023JJ60503National Natural Science Foundation of China 71874209UK National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation at the University of Bristol NIHR200877UK NIHR NIHR133208Wellcome TrustWellcome Trust WT 220866/Z/20/Z
6 · The paper itself

Abstract

BACKGROUND/

aimsThe World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.

methodsUsing an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022-2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths.

resultsThe strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022-2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868).

conclusionAchieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.

Indexed as

Cost-Benefit AnalysisDisease EradicationHepatitis CAntiviral AgentsChinaDisability-Adjusted Life YearsHepacivirusHumansIncidenceMass ScreeningQuality-Adjusted Life YearsAntiviral AgentsChinaCost-effectiveness analysisDisease eradicationHepatitis COutcome assessment, health care

Identifiers

PMID39623958
PMCPMC12016657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.